Latest news with #BSX
Yahoo
2 days ago
- Business
- Yahoo
24-Acre Minnetonka Complex Put Up for Sale by Boston Scientific (BSX)
Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to buy. On June 10, the company announced that it is selling one suburban Twin Cities property and expanding another, mirroring a pattern of companies centralizing in fewer but more dynamic sites. BSX has placed its 226,000 square foot Minnetonka campus on the market, indicating the wind-down of its presence in that suburb. Meanwhile, it is enlarging its Maple Grove operations with a new 52,000 square foot buildout at its 79-acre Weaver Lake location. That $139.4 million development seems relatively small beside Boston Scientific's second Maple Grove site, which is a $170 million, 400,000 square foot facility where staff are expected to begin moving in before year's end. A surgeon examining a patient's brain in an operating room, paramedics nearby. CBRE's listing describes the Minnetonka property as containing labs, warehousing, and top-tier offices. Though no asking price is listed, county records place the combined 2025 value of four adjacent parcels at $14.8 million. Boston Scientific employed around 10,000 people in Minnesota as of March, including sites in Minnetonka, Maple Grove, and a sizable Arden Hills facility. The number of employees has roughly doubled over 15 years. Despite its Massachusetts roots, the company runs all eight of its divisions in Minnesota, including its flagship cardiology arm. The company did not respond to specific queries about the Minnetonka sale, including the functions housed there or implications for workforce downsizing. The real estate listing indicates the company may lease the site until mid-2026 but plans a complete exit thereafter. Boston Scientific Corporation (NYSE:BSX), a global player in medical device innovation, operates through its Cardiovascular and MedSurg segments to deliver advanced diagnostic and therapeutic technologies. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Boston Scientific's Q1 Earnings Call: Our Top 5 Analyst Questions
Boston Scientific's first quarter results were met with a positive market reaction following revenue and profit that surpassed Wall Street expectations. Management credited robust growth in its cardiology portfolio and the successful execution of a category leadership strategy spanning electrophysiology, WATCHMAN, and interventional cardiology products. CEO Michael Mahoney highlighted that double-digit expansion in the U.S. and momentum in Europe and Japan helped drive operational sales growth, while new product launches and increased adoption in emerging segments, such as FARAPULSE and Axios, also contributed to performance. Is now the time to buy BSX? Find out in our full research report (it's free). Revenue: $4.66 billion vs analyst estimates of $4.57 billion (20.9% year-on-year growth, 2% beat) Adjusted EPS: $0.75 vs analyst estimates of $0.67 (11.5% beat) Revenue Guidance for Q2 CY2025 is $4.88 billion at the midpoint, above analyst estimates of $4.79 billion Management raised its full-year Adjusted EPS guidance to $2.91 at the midpoint, a 2.5% increase Operating Margin: 19.8%, up from 17.5% in the same quarter last year Organic Revenue rose 18.2% year on year (13.1% in the same quarter last year) Market Capitalization: $150.5 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Robert Marcus (JPMorgan) asked about mitigating tariff headwinds. CFO Daniel Brennan explained the offset through increased revenue and targeted cost reductions, with no plans for major manufacturing shifts. Larry Biegelsen (Wells Fargo) questioned global electrophysiology market share. CEO Michael Mahoney acknowledged strong momentum and the goal of reaching #1, particularly through investments in China and Japan. Joanne Wuensch (Citi) inquired about WATCHMAN's growth and procedural trends. Mahoney and Dr. Ken Stein cited rapid adoption of concomitant procedures and favorable clinical data as key drivers. Travis Steed (Bank of America) asked about margin sustainability. Brennan attributed margin expansion to product mix and noted that tariffs will pressure gross margin in the second half, but full-year expansion is still expected. Danielle Antalffy (UBS) raised questions on the SoniVie acquisition's timing and potential. Mahoney described the clinical trial process and anticipated a multi-year path to realizing commercial contributions. In upcoming quarters, the StockStory team will monitor (1) continued growth and market share gains in electrophysiology and WATCHMAN, (2) progress on integrating new acquisitions and the resulting product launches, and (3) the company's ability to offset tariff-related cost pressures without sacrificing margin targets. Updates on key clinical trials and regulatory milestones will also be critical to tracking Boston Scientific's strategy execution. Boston Scientific currently trades at $101.38, up from $94.97 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
Forbes
6 days ago
- Business
- Forbes
What's Happening With Boston Scientific Stock?
CHONGQING, CHINA - APRIL 20: In this photo illustration, the logo of Boston Scientific Corporation ... More is displayed on a smartphone screen, with the company's branding and slogan Advancing science for life in the background, representing the American biomedical and biotechnology engineering firm known for developing medical devices used in interventional medical specialties, on April 20, 2025, in Chongqing, China. (Photo by) Boston Scientific (NYSE:BSX) has experienced a stock price increase of over 30% in the last twelve months, greatly exceeding the S&P 500's gain of 9%. This remarkable performance can be credited to the launch of new products, which have enhanced sales growth and widened profit margins. Nonetheless, the pivotal question for investors is whether the BSX stock, currently priced at around $100, offers a worthwhile buying opportunity. We believe that at its current valuation, Boston Scientific seems relatively overpriced, especially when compared to the broader market and its historical performance metrics. That being said, if you are looking for potential upside with less volatility than individual stocks, the Trefis High-Quality portfolio serves as an option – having outperformed the S&P 500 and yielding returns of over 91% since its inception. Additionally, take a look at – Will Adobe Stock See Higher Levels? When examining Boston Scientific's valuation in relation to the S&P 500, the stock appears quite pricey across essential metrics. The company's price-to-sales (P/S) ratio is at 8.3, notably greater than the S&P 500's 3.0. Likewise, its price-to-free cash flow (P/FCF) ratio of 38.0 significantly surpasses the benchmark's 20.5. Moreover, Boston Scientific's price-to-earnings (P/E) ratio stands at a notable 71.4, as opposed to the S&P 500's 26.4. These numbers collectively suggest that investors are paying a considerable premium for Boston Scientific's sales, profits, and cash flow relative to the overall market. Check out – Boston Scientific's Valuation Ratios – for further insights. Boston Scientific has shown significant revenue growth in recent years. Over the past three years, its revenues have increased at an average rate of 13.1%, dramatically outpacing the S&P 500's rise of 5.5%. More recently, Boston Scientific's revenues increased by 19.4% over the past twelve months, climbing from $15 billion to $18 billion. In its latest quarter, quarterly revenues experienced a solid rise of 20.9%, growing from $3.9 billion to $4.7 billion compared to the previous year. These figures highlight the company's robust operational momentum in driving sales. The company's profit margins typically reside around the average for firms within the Trefis coverage universe. Over the past four quarters, Boston Scientific's operating income totaled $3.2 billion, yielding a solid operating margin of 18.5%, which exceeds the S&P 500's 13.2%. Boston Scientific's Operating Cash Flow (OCF) for the same period was $3.8 billion, reflecting a good OCF margin of 21.7%, compared to the S&P 500's 14.9%. Boston Scientific's Net Income over the last four quarters was $2.0 billion, resulting in a moderate net income margin of 11.6%, which aligns with the average of the S&P 500. Boston Scientific's balance sheet appears to be moderate. As of the latest quarter, the company's debt was $12 billion, in contrast to a significant market capitalization of $147 billion (as of June 13, 2025). This results in a strong Debt-to-Equity Ratio of 8.1%, which is substantially lower and more favorable than the S&P 500's 19.9%. However, a slight concern arises from its cash position; cash and cash equivalents totaling $725 million yield a suboptimal Cash-to-Assets Ratio of 1.8% compared to total assets of $40 billion, and significantly lower than the S&P 500's 13.8%. Boston Scientific's stock has exhibited mixed performance during previous market downturns, sometimes performing worse than the S&P 500. During the "Inflation Shock" of 2022, BSX stock faced a decline of 25.2%, closely mirroring the S&P 500's decrease of 25.4%, but fully recovered by December 2022. The COVID-19 pandemic in 2020 had a more severe impact, causing BSX stock to drop 43.5% in contrast to a 33.9% fall for the S&P 500; however, it regained its value by August 2021. The Global Financial Crisis of 2008 posed the most significant challenge, with BSX stock plunging 70.5% compared to the S&P 500's decline of 56.8%, and it took until November 2015 for the stock to completely recover. In conclusion, Boston Scientific demonstrates 'Extremely Strong' growth, 'Strong' profitability, and a 'Neutral' financial stability profile. Nevertheless, its 'Weak' resilience during downturns and, particularly, its 'Very High' valuation contribute to an 'Overall Neutral' evaluation. The current price-to-sales ratio of 8.3x is significantly higher than Boston Scientific's historical average of 5.9x, indicating that the stock is currently trading at a substantial premium. Although Boston Scientific's improving sales growth and profitability are encouraging factors that may continue attracting investor interest, the high valuation at this time poses an increased risk. For investors looking for upside with reduced volatility relative to individual stocks, portfolios such as the Trefis High Quality (HQ) portfolio and Reinforced Value (RV) Portfolio provide alternatives. The HQ Portfolio, focusing on risk assessment and consisting of 30 stocks, has a proven history of outperforming the S&P 500 over the last four years, yielding superior returns with less risk. Similarly, the RV Portfolio, which is rebalanced quarterly with a mix of large, mid, and small-cap stocks, has outperformed its all-cap stocks benchmark.
Yahoo
13-06-2025
- Business
- Yahoo
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?
Boston Scientific's BSX Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions using innovative, less invasive technologies. The company is strategically positioned to benefit from the expanding global endoscopy devices market through its strong innovation pipeline and well-diversified product offerings. Per an Allied Market Research report, the global endoscopy devices market was valued at $28.1 billion in 2022 and is projected to reach $44.1 billion by 2032 at a CAGR of 4.6% from 2023 to 2032. Sales of Endoscopy products totaled $673 million, up 6% both operationally and organically, for the first quarter of 2025. Endoscopy sales accounted for 14% of the company's overall revenues. Sales growth can be attributed to steady performance across geographies and BSX's diverse product suite. A key highlight was the continued double-digit growth of the AXIOS Stent and Electrocautery Enhanced Delivery System. AXIOS is the first and only stent indicated for transgastric or transduodenal endoscopic drainage of symptomatic pancreatic pseudocysts. Additionally, the Endoluminal Surgery franchise saw double-digit growth from two innovative technologies — OverStitch and MANTIS Clip. This indicates robust adoption of advanced endoscopic tools aimed at minimally invasive procedures. The segment's consistent growth is attributed to its balanced regional performance and strong traction in newer, high-potential product lines. Accordingly, Boston Scientific is poised to sustain long-term growth in the high-potential endoscopy space. Stryker's SYK Endoscopy segment posted strong growth in the first quarter, with U.S. organic sales rising 11.1%, driven by double-digit gains in core endoscopy and sports medicine portfolios. Key growth catalysts included the 1788 camera platform, as it continues to win customers. Robust global performance and product innovation position the segment for continued success. Johnson & Johnson JNJ, through its subsidiary Ethicon, is a key player in the field of endoscopy. The company offers advanced energy-based endoscopic surgery platforms known as ENDOPATH and HARMONIC. Additionally, it provides staplers and suturing devices such as ECHELON and PROXISURE. JNJ's strategic growth initiatives involve a strong emphasis on digital surgery platforms, artificial intelligence and analytics to enhance endoscopic procedures. Shares of Boston Scientific have gained 27.3% in the past year compared with the industry's growth of 9.7%. The S&P 500 composite has also grown 11% in the same period. Image Source: Zacks Investment Research From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 32.13X, above the industry's 21.33X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for BSX's earnings has been on the rise over the past 60 days. Image Source: Zacks Investment Research BSX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
10-06-2025
- Business
- Globe and Mail
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029. With its portfolio of Cardiology and Peripheral Interventions products, Boston Scientific is set to benefit significantly from this upward trend. The booming cardiovascular devices market, driven by aging demographics, minimally invasive procedures, and tech innovation, is propelling Boston Scientific's top-line growth, product leadership and stronger profitability. These tailwinds were clearly reflected in the company's robust first-quarter 2025 performance and raised full-year 2025 guidance. In the past year, Boston Scientific's shares have skyrocketed roughly 31.8%, outpacing the broader Medical Product industry and the S&P 500 benchmark, which have improved about 8.9% and 11.9%, respectively. During this time, Boston Scientific has also outpaced key peers such as Abbott Laboratories ABT and Medtronic MDT. While Abbott, known for its structural heart, cardiac rhythm management, and diagnostics products, gained 24.2%, Medtronic, known for heart valves and coronary stents, advanced 5.1%. BSX 1 Year Price Comparison Major Tailwinds Driving BSX Stock Strong Q1: In the first quarter of 2025, Boston Scientific's revenues were up 22.2% on an operational basis (at a constant exchange rate or CER). The Cardiovascular segment sales were up 26.2% year over year. Within this, Cardiology and Peripheral Interventions businesses' sales grew 31.2% and 7.4%, respectively, year over year. U.S. revenues rose 31%, driven by double-digit growth in most business units. Japan and China also delivered strong results, particularly in EP. Boston Scientific reported adjusted earnings per share (EPS) of $0.75, up 34% year over year. The company's revenues and EPS rose due to exceptional top-line growth across key franchises, especially in EP and structural heart, combined with improved margin performance and disciplined cost management. Cardiovascular Steals Spotlight: Boston Scientific's Electrophysiology business is rapidly expanding its global market share, with first-quarter 2025 organic growth surging 145%, positioning BSX as the number two player in the space. This growth is largely driven by strong commercial adoption of FARAPULSE, the company's flagship Pulsed Field Ablation ('PFA') system, which is gaining traction through global demand, new account expansions, and ongoing clinical studies like AVANT GUARD and Elevate PF. Meanwhile, Boston Scientific's structural heart portfolio is also performing well, with WATCHMAN sales up 24% year over year, aided by DRG-enabled procedural growth. Next-gen versions — WATCHMAN FLX and FLX Pro — are accelerating adoption, while trials like CHAMPION-AF and OPTION A aim to expand the device's global market potential. Boston Scientific's 2025 Outlook Looks Promising For full-year 2025, Boston Scientific raised its organic revenue growth guidance to 12- 14% (from 10-12%) and now expects adjusted EPS of $2.87-$2.94, representing 14-17% year-over-year growth. Reported revenue growth is projected at 15-17%, including contributions from recent acquisitions like Axonics and Intera Oncology. Adjusted operating margin is expected to expand 50-75 basis points, driven by strong product mix, notably FARAPULSE and WATCHMAN, and cost efficiencies. Segmentally, Cardiology continues to lead growth, with Endoscopy and Neuromodulation expected to outperform markets and Urology affected modestly by supply constraints. Estimates for BSX Heading North The Zacks Consensus Estimate for Boston Scientific's 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. The bottom-line estimates have moved northward in the past 60 days. BSX's Downsides Boston Scientific continues to face a challenging business environment, thanks to industry-wide macroeconomic pressures, including geopolitical tensions, global supply-chain disruptions, and labor market instability. International conflicts and retaliatory trade actions have increased global risks, while volatile financial markets and fluctuating prices for goods and services are squeezing profitability. Sustained macroeconomic pressures may make it more difficult for the company to manage operating expenses effectively. Tariffs are expected to have a $200 million impact in 2025, which, although planned to be offset through sales growth, cost controls and FX benefits, underscores the heightened complexity of the current environment. BSX Stock Valuation With a forward five-year price-to-earnings (P/E) of 33.31X, Boston Scientific's shares are trading at a premium compared with the industry average of 21.29X. It has a Value Score of D at present. P/E Forward Twelve Months (F12M) Meanwhile, MDT's five-year price-to-earnings (P/E) of 15.63X is lower than the industry average. How to Play BSX Stock? Considering Boston Scientific's strong operational performance, leadership in fast-growing cardiovascular segments like Electrophysiology and Structural Heart, and promising pipeline of developments, the company is clearly executing well on both growth and profitability fronts. With projected double-digit revenue and earnings growth, BSX is poised to continue delivering shareholder value, even amid a complex macroeconomic backdrop and tariff headwinds. The stock has excelled both the industry and its peers, and its estimates are likely to continue to trend upward in the near term. Henceforth, the current BSX shareholders may find it prudent to stay invested. Boston Scientific carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report
